KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EPS (Basic) (2017 - 2025)

Historic EPS (Basic) for Aquestive Therapeutics (AQST) over the last 8 years, with Q3 2025 value amounting to -$0.14.

  • Aquestive Therapeutics' EPS (Basic) fell 769.23% to -$0.14 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.71, marking a year-over-year decrease of 5434.78%. This contributed to the annual value of -$0.51 for FY2024, which is 29147.96% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' EPS (Basic) stood at -$0.14, which was down 769.23% from -$0.14 recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year EPS (Basic) high stood at $0.15 for Q1 2023, and its period low was -$0.76 during Q4 2021.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.2 (2024), whereas its average is -$0.22.
  • Its EPS (Basic) has fluctuated over the past 5 years, first plummeted by 38017.03% in 2021, then surged by 14687.5% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' EPS (Basic) (Quarter) stood at -$0.76 in 2021, then skyrocketed by 66.66% to -$0.25 in 2022, then surged by 48.71% to -$0.13 in 2023, then tumbled by 51.27% to -$0.2 in 2024, then grew by 28.81% to -$0.14 in 2025.
  • Its EPS (Basic) was -$0.14 in Q3 2025, compared to -$0.14 in Q2 2025 and -$0.24 in Q1 2025.